Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
RegulatoryapprovedciprocopanPositive
AI Analysis
Summary
Nuvectis Pharma announced marketing approval of ciprocopan (NXP100) from China's NMPA for treatment-naive PNH patients. This represents a significant regulatory milestone and international expansion for the once-daily oral complement Factor B inhibitor.
Outcome Details
Marketing approval from China's National Medicinal Products Administration (NMPA) for ciprocopan in treatment-naive PNH patients
Importance:8/10
Sentiment:
0.90
regulatory approvalChina NMPAcomplement inhibitorPNHinternational expansion
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 23, 2026 1:00 PM